human
***TASK*** the task is to summarize an input biomedical literature in six sentences 
    ***INPUT*** the input is a biomedical literature 
    ***OUTPUT*** the output is the summary of an input biomedical literature in six sentences 
    ***DOCUMENTATION*** 
    ***EXAMPLES*** 
    Input: OBJECTIVE To compare the safety and efficacy of a combination of vinorelbine and epirubicin ( NE ) with fluorouracil/epirubicin/cyclophosphamide ( FEC ) as a postoperative adjuvant chemotherapy for breast cancer . METHODS Breast cancer patients were treated postoperatively in Jiangsu Cancer Hospital and Research Institute from 1997 to 2006 with either the NE regimen ( vinorelbine 40 mg/m2 iv on day 1 and day 8 , epirubicin 50 mg/m2 iv on day 1 and day 2 , and a cycle repeated every 21 - 28 days for totally 4 - 6 cycles ) or the FEC regimen ( 5-Fu 500 mg/m2 iv gtt on day 1 , epirubicin 50 mg/m2 iv on day 1 and day 2 , CTX 500 mg/m2 iv on day 1 and a cycle repeated every 21 - 28 days for totally 4 - 6 cycles ) . Toxicity was evaluated after each cycle of chemotherapy . RESULTS Main side effects in both NE and FEC groups were neutropenia and gastrointestinal syndrome , with a 5 year survival rate of 87.9 % in the NE and 85.2 % in the FEC group . CONCLUSIONS NE regimen is safe with good long-term survival rate , and thus could be recommended as a postoperative chemotherapy regimen for breast cancer Adjuvant chemotherapy increases disease-free survival ( DFS ) and overall survival ( OS ) following surgery for breast cancer . However , debates concerning the type of adjuvant chemotherapy continue . The effect of adjuvant chemotherapy on loco-regional recurrence-free survival ( LFS ) was also reported . The present study was undertaken to compare the results of adjuvant FAC ( 5-fluorouracil , Doxorubicin , Cyclophosphamide ) and CMF ( Cyclophosphamide , Methotrexate , 5-fluorouracil ) chemotherapy on DFS , OS and LFS for node positive breast carcinoma treated with mastectomy in a non-r and omised setting . Data from 688 consecutive lymph node positive breast cancer patients who underwent radical or modified radical mastectomy and received adjuvant FAC ( 600/60/600 mgr/m2 for 6 cycles every three weeks ) or CMF ( 600/40/600 mgr/m2 for 6 cycles on days l and 8 every four weeks ) chemotherapy were review ed . The effect of FAC on DFS , OS and LFS as compared with CMF was analysed . Survival curves were generated by the Kaplan-Meier method , and a multivariate analysis was performed by the Cox proportional hazard model . Adjuvant FAC was found to improve DFS , OS and LFS . 5-year DFS , OS and LFS were longer for patients treated with FAC as compared to CMF ( 67 % versus 53 % , p < 0.001 ; 77 % versus 66 % , p < 0.001 , and 97 % versus 91 % ) . Adjusted hazard ratio ( HR ) for potential risk factors and tamoxifen treatment showed that FAC treated patients much benefitted in terms of survival as compared to CMF treated patients ( HR 0.53 , CI 0.40 - 0.69 for DFS ; HR 0.48 , CI 0.35 - 0.65 for OS , and HR 0.33 , CI 0.16 - 0.65 for LFS ) . In conclusion , adjuvant FAC improves DFS , OS and LFS as compared to CMF in node positive breast carcinoma patients treated with mastectomy 
    Output:
    
agent
***TASK*** the task is to summarize an input biomedical literature in six sentences 
    ***INPUT*** the input is a biomedical literature 
    ***OUTPUT*** the output is the summary of an input biomedical literature in six sentences 
    ***DOCUMENTATION*** 
    ***EXAMPLES*** 
    Input: OBJECTIVE To compare the safety and efficacy of a combination of vinorelbine and epirubicin ( NE ) with fluorouracil/epirubicin/cyclophosphamide ( FEC ) as a postoperative adjuvant chemotherapy for breast cancer . METHODS Breast cancer patients were treated postoperatively in Jiangsu Cancer Hospital and Research Institute from 1997 to 2006 with either the NE regimen ( vinorelbine 40 mg/m2 iv on day 1 and day 8 , epirubicin 50 mg/m2 iv on day 1 and day 2 , and a cycle repeated every 21 - 28 days for totally 4 - 6 cycles ) or the FEC regimen ( 5-Fu 500 mg/m2 iv gtt on day 1 , epirubicin 50 mg/m2 iv on day 1 and day 2 , CTX 500 mg/m2 iv on day 1 and a cycle repeated every 21 - 28 days for totally 4 - 6 cycles ) . Toxicity was evaluated after each cycle of chemotherapy . RESULTS Main side effects in both NE and FEC groups were neutropenia and gastrointestinal syndrome , with a 5 year survival rate of 87.9 % in the NE and 85.2 % in the FEC group . CONCLUSIONS NE regimen is safe with good long-term survival rate , and thus could be recommended as a postoperative chemotherapy regimen for breast cancer Adjuvant chemotherapy increases disease-free survival ( DFS ) and overall survival ( OS ) following surgery for breast cancer . However , debates concerning the type of adjuvant chemotherapy continue . The effect of adjuvant chemotherapy on loco-regional recurrence-free survival ( LFS ) was also reported . The present study was undertaken to compare the results of adjuvant FAC ( 5-fluorouracil , Doxorubicin , Cyclophosphamide ) and CMF ( Cyclophosphamide , Methotrexate , 5-fluorouracil ) chemotherapy on DFS , OS and LFS for node positive breast carcinoma treated with mastectomy in a non-r and omised setting . Data from 688 consecutive lymph node positive breast cancer patients who underwent radical or modified radical mastectomy and received adjuvant FAC ( 600/60/600 mgr/m2 for 6 cycles every three weeks ) or CMF ( 600/40/600 mgr/m2 for 6 cycles on days l and 8 every four weeks ) chemotherapy were review ed . The effect of FAC on DFS , OS and LFS as compared with CMF was analysed . Survival curves were generated by the Kaplan-Meier method , and a multivariate analysis was performed by the Cox proportional hazard model . Adjuvant FAC was found to improve DFS , OS and LFS . 5-year DFS , OS and LFS were longer for patients treated with FAC as compared to CMF ( 67 % versus 53 % , p < 0.001 ; 77 % versus 66 % , p < 0.001 , and 97 % versus 91 % ) . Adjusted hazard ratio ( HR ) for potential risk factors and tamoxifen treatment showed that FAC treated patients much benefitted in terms of survival as compared to CMF treated patients ( HR 0.53 , CI 0.40 - 0.69 for DFS ; HR 0.48 , CI 0.35 - 0.65 for OS , and HR 0.33 , CI 0.16 - 0.65 for LFS ) . In conclusion , adjuvant FAC improves DFS , OS and LFS as compared to CMF in node positive breast carcinoma patients treated with mastectomy 
    Output:
    